Adlai Nortye (FRA:N2U0) Beginning Cash Position : €0.00 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Beginning Cash Position?

Adlai Nortye's Beginning Cash Position for the quarter that ended in Jun. 2024 was €0.00 Mil.

Adlai Nortye's quarterly Beginning Cash Position declined from Jun. 2023 (€55.23 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€0.00 Mil).

Adlai Nortye's annual Beginning Cash Position increased from Dec. 2021 (€21.47 Mil) to Dec. 2022 (€60.54 Mil) but then declined from Dec. 2022 (€60.54 Mil) to Dec. 2023 (€39.21 Mil).

Adlai Nortye Beginning Cash Position Historical Data

The historical data trend for Adlai Nortye's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Beginning Cash Position Chart

Adlai Nortye Annual Data

Trend

Dec21

Dec22

Dec23

Beginning Cash Position

21.47

60.54

39.21

Adlai Nortye Quarterly Data
	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Jun24
Beginning Cash Position	Get a 7-Day Free Trial			-	39.94	55.23	-	-

Adlai Nortye Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Adlai Nortye Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (FRA:N2U0) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ANL:USA

Address

685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902

Website

https://www.adlainortye.com

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Adlai Nortye Headlines

No Headlines